#Cambridge #Australia #CAR therapy #Monash University #CREATE Medicines

CREATE Medicines Expands Targeted In Vivo CAR Platform Through Monash University Partnership

In a significant advancement for the field of biotechnology, CREATE Medicines, a pioneering clinical-stage company focused on in vivo immune programming, has officially announced a strategic collaboration with Australia’s Monash University. This partnership aims to broaden the company’s in vivo cell therapy capabilities through access to cutting-edge lipid nanoparticle (LNP) technologies developed at the world-renowned Monash Institute of Pharmaceutical Sciences (MIPS).

The New Collaboration

This collaboration encompasses an exclusive license agreement that allows CREATE Medicines to utilize Monash’s proprietary LNP technologies. These advanced chemistries and delivery mechanisms will enhance CREATE’s existing targeted in vivo Chimeric Antigen Receptor (CAR) therapy platform, crucial for the precise delivery of therapeutic payloads to specific immune cells.

Achieving effective and targeted delivery is pivotal for realizing the full potential of in vivo therapies, which can significantly improve patient outcomes in various disease contexts. Under this agreement, CREATE will also receive worldwide exclusive rights to all intellectual property generated through the partnership, alongside the privileges to develop and market CAR products aimed at designated targets.

Targeted Delivery Model

CREATE Medicines has taken steps to address one of the most persistent challenges within the biotherapeutics environment—targeted delivery. The combination of CREATE’s clinically validated mRNA-LNP platform with Monash University's expertise in LNP design is expected to yield a new generation of programmable medicines. Daniel Getts, CEO of CREATE Medicines, expressed enthusiasm regarding this potential, highlighting that the partnership allows for the application of precision treatment methods across a wider array of therapeutic targets.

Robert Hofmeister, Chief Scientific Officer of CREATE, noted that the collaboration enhances their toolkit for targeting immune cells more effectively, enabling new binder formats and controls that can program specific cells with greater accuracy.

Expert Leadership from Monash University

Professor Angus Johnston will lead the research efforts at Monash, bringing his extensive background in nanoparticle delivery biology and intracellular trafficking to the collaboration. He will work alongside noted professors Colin Pouton and Moore Chen, who have previously contributed groundbreaking research to the field of mRNA delivery.

Professor Johnston remarked on the importance of targeted delivery in the realm of in vivo therapies, stating that the partnership between CREATE and Monash marks a significant step towards addressing this challenge.

Broad Impacts on Healthcare

The implications of this collaboration extend beyond the laboratory. As stated by Monash Vice-Chancellor, Professor Sharon Pickering, this partnership is poised to accelerate the work of leading pharmaceutical researchers at Monash, potentially leading to the development of new immunotherapies and treatments for cancer. The synergy between academic research and industry practices is expected to yield transformative health outcomes for patients globally.

As biotechnologies evolve at an unprecedented pace, collaborations like that of CREATE Medicines and Monash University exemplify the modern approach to health and medical innovation. By leveraging each other’s strengths, both parties aim to push the boundaries of what is possible in therapeutic development, ultimately working towards delivering better healthcare solutions.

About CREATE Medicines

CREATE Medicines is at the forefront of the biotech industry, focusing on in vivo CAR therapy. Their proprietary platform enables the direct programming of immune cells within the body, offering scalable and repeatable off-the-shelf immunotherapies. With a proven record in human validation, CREATE is actively advancing its portfolio of in vivo CAR therapies aimed at improving results in both cancer and autoimmune disease treatment landscapes.

For more information, visit CREATE Medicines.

About Monash University

Monash University, Australia’s largest university, is known for its commitment to world-leading research and educational excellence. With a footprint that includes campuses across Australia and around the world, Monash is well-poised to harness international collaboration in tackling global health challenges.

For further details, visit Monash University.